Literature DB >> 21354033

[Healing and targeted therapies: Management in perioperative period?].

G Pignot1, T Lebret, D Chekulaev, M Peyromaure, D Saighi, T Flam, D Amsellem-Ouazana, B Debre, M Zerbib.   

Abstract

INTRODUCTION: In the era of new-targeted therapies and neoadjuvant strategies, this article highlights the role of angiogenesis in the process of physiological wound healing with a review of literature about parietal complications under anti-angiogenic therapies.
METHODS: Research on Medline was carried out using the terms renal cell carcinoma, angiogenesis, wound healing, targeted therapies, and complications.
RESULTS: The frequency of these complications varies between 5 and 50% in recent series. These results depend on half-lives of each drug and perioperative management (before and after surgical procedure).
CONCLUSION: In the absence of current recommendations, it is advised to stop bevacizumab at least five weeks before a surgical intervention and to take it back 4 weeks later. For the tyrosine kinase inhibitors, the treatment can be stopped 24-48 hours before the surgery and taken back 3-4 weeks later. Finally, for the mTOR inhibitors, it is advised to stop the treatment 7-10 days before and to take back it at least 3 weeks later.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21354033     DOI: 10.1016/j.purol.2010.09.023

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  1 in total

1.  Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Akihiro Nakajo; Hideo Arima; Yoshiaki Shinden; Tetsuya Ijichi; Yuka Eguchi; Hiroshi Okumura; Yoshikazu Uenosono; Hiroshi Kurahara; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2014-05-16       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.